Chemodex

MK-4827 tosylate

Product Code:
 
CDX-M0565
Product Group:
 
Inhibitors and Activators
Supplier:
 
Chemodex
Regulatory Status:
 
RUO
Shipping:
 
AMBIENT
Storage:
 
Short Term: +4°C, Long Term: -20°C
1 / 1
Chemical Structure

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
CDX-M0565-M01010 mg£205.00
Quantity:
CDX-M0565-M05050 mg£437.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Alternate Names/Synonyms:
Niraparib tosylate; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 4 methylbenzenesulfonate
Appearance:
White to off-white solid.
CAS:
1038915-73-9
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
InChiKey:
LCPFHXWLJMNKNC-PFEQFJNWSA-N
Long Description:
Chemical. CAS: 1038915-73-9. Formula: C19H20N4O . C7H8O3S. MW: 492.6. Synthetic. MK-4827 is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC50s=3.8 and 2.1nM, respectively). It inhibits the proliferation of cancer cells carrying the breast cancer mutations BRCA1 and BRCA2 in vitro and has efficacy alone against a xenograft of BRCA1-deficient cancer in mice. MK-4827 sensitizes human lung and breast cancer xenografts to radiation in mice.3 Formulations containing MK-4827 are effective against ovarian cancer.
MDL:
MFCD28167748
Molecular Formula:
C19H20N4O . C7H8O3S
Molecular Weight:
492.6
Package Type:
Vial
Product Description:
MK-4827 is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC50s=3.8 and 2.1nM, respectively). It inhibits the proliferation of cancer cells carrying the breast cancer mutations BRCA1 and BRCA2 in vitro and has efficacy alone against a xenograft of BRCA1-deficient cancer in mice. MK-4827 sensitizes human lung and breast cancer xenografts to radiation in mice.3 Formulations containing MK-4827 are effective against ovarian cancer.
Purity:
>99% (HPLC)
SMILES:
NC(C1=CC=CC2=CN(C3=CC=C([C@H]4C[NH2+]CCC4)C=C3)N=C21)=O.CC5=CC=C(S(=O)([O-])=O)C=C5
Solubility Chemicals:
Soluble in DMSO or DMF (both 20mg/ml). Sparingly soluble in ethanol (1mg/ml) or water (<1mg/ml).
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

(1) P. Jones, et al.; J. Med. Chem. 52, 7170 (2009) | (2) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (3) L. Wang, et al.; Invest. New Drugs 30, 2113 (2012) | (4) M.R. Mirza, et al.; N. Engl. J. Med. 375, 2154 (2016) | (5) K.N. Moore, et al.; Gynecol. Oncol. 149, 214 (2018) (Review)